Minireview: Fibroblast growth factor 23 in phosphate homeostasis and bone metabolism

Endocrinology

Volumn 152, Issue 1, 2011, Pages 4-10

  Hori, Michiko ^a   Shimizu, Yuichiro ^a   Fukumoto, Seiji ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PHOSPHATE;

BONE METABOLISM; CHRONIC KIDNEY DISEASE; DRUG MECHANISM; FIBROUS DYSPLASIA; GENETIC CODE; HOMEOSTASIS; HUMAN; HYPOPHOSPHATEMIA; NONHUMAN; ONCOGENIC OSTEOMALACIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SEBACEOUS NEVUS; X LINKED HYPOPHOSPHATEMIC RICKETS;

ANIMALS; BONE AND BONES; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; PHOSPHATES;

EID: 78650833297     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0800     Document Type: Review

References (63)

1. Itoh N, Ornitz D M 2004 Evolution of the Fgf and Fgfr gene families. Trends Genet 20:563-569
2. Moore DD 2007 Physiology. Sister act. Science 316:1436-1438
3. ADHR Consortium 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348
4. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505
5. Yamashita T, Yoshioka M, Itoh N 2000 Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277:494-498
6. Benet-Pagès A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom T M 2004 FGF23 is processed by proprotein convertases but not by PHEX. Bone 35:455-462
7. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ 2001 Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079-2086
8. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M 2006 Regulation offibroblast growth factor-23 signaling by klotho.J Biol Chem 281:6120-6123
9. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T 2006 Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774
10. Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H, Fujita T, Kuroki R, Yamashita T, Fukumoto S, Shimada T 2008 Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 23:1509-1518
11. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate ho-meostasis. J Bone Miner Res 19:429-435
12. Brown WW, Jüppner H, Langman CB, Price H, Farrow EG, White KE, McCormick KL 2009 Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaph-yseal chondrodysplasia. J Clin Endocrinol Metab 94:17-20
13. White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa S, Fields J, Yu X, Shaw NJ, McLellan NJ, McKeown C, Fitzpatrick D, Yu K, Ornitz DM, Econs MJ 2005 Mutations that cause osteoglo-phonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76:361-367
14. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jande Beur SM, Mentzel T, Mont-gomery E, Michal M, Miettinen M, Mills SE, Reith JD, O'Connell JX, Rosenberg A E, Rubin BP, Sweet DE, Vinh T N, Wold LE, Wehrli BM, White KE, Zaino RJ, Weiss SW 2004 Most osteomalacia-as-sociated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1-30
15. Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, Jan De Beur SM, Schiavi SC, Kumar R 2003 Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent.J Clin Invest 112:785-794
16. Carpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R 2005 Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 90:1012-1020
17. Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR 2004 MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34:303-319
18. Fukumoto S, Takeuchi Y, Nagano A, Fujita T 1999 Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone 25:375-377
19. Jan de Beur SM, Streeten EA, Civelek AC, McCarthy EF, Uribe L, Marx SJ, Onobrakpeya O, Raisz LG, Watts NB, Sharon M, Levine MA 2002 Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359:761-763
20. Roarke M C, Nguyen B D 2007 PET/CT localizationofphosphaturic mesenchymal neoplasm causing tumor-induced osteomalacia. Clin Nucl Med 32:300-301
21. Ito N, Shimizu Y, Suzuki H, Saito T, Okamoto T, Hori M, Akahane M, Fukumoto S, Fujita T 2010 Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia. J Intern Med 268:390-394
22. Takeuchi Y, Suzuki H, Ogura S, Imai R, Yamazaki Y, Yamashita T, Miyamoto Y, Okazaki H, Nakamura K, Nakahara K, Fukumoto S, Fujita T 2004 Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 89:3979-3982
23. The HYP Consortium 1995 A gene (PEX) with homologies to en-dopeptidases is mutated in patients with X-linked hypophos-phatemic rickets. Nat Genet 11:130-136
24. Jonsson K B, Zahradnik R, Larsson T, White K E, Sugimoto T, Iman-ishiY, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H 2003 Fibroblast growthfactor23inoncogenic osteomalacia andX-linked hypophosphatemia. N Engl J Med 348:1656-1663
25. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960
26. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Jüppner H, Lanske B 2004 Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23:421-432
27. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2002 Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophos-phatemia in vivo. Endocrinology 143:3179-3182
28. Bai XY, Miao D, Goltzman D, Karaplis AC 2003 The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843-9849
29. Imel EA, Hui SL, Econs MJ 2007 FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22:520-526
30. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE 2006 Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-1315
31. Lorenz-Depiereux B, Bastepe M, Benet-Pagès A, Amyere M, Wa-genstaller J, Mü ller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Jüppner H, Strom TM 2006 DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:1248-1250
32. Liu S, Zhou J, Tang W, Menard R, Feng JQ, Quarles LD 2008 Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endo-crinol Metab 295:E254-E261
33. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, Manor E, Buriakovsky S, Hadad Y, Goding J, Parvari R 2010 Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86:273-278
34. Lorenz-Depiereux B, Schnabel D, Tiosano D, HäuslerG, Strom TM 2010 Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophos-phatemic rickets. Am J Hum Genet 86:267-272
35. Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsu-moto T 2008 Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 42:1235-1239
36. Ruf N, Uhlenberg B, Terkeltaub R, Nurnberg P, Rutsch F 2005 The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI). Hum Mutat 25:98
37. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Höhne W, Schauer G, Lehmann M, Roscioli T, Schnabel D, Epplen JT, Knisely A, Superti-Furga A, McGill J, Filippone M, Sinaiko AR, Vallance H, Hinrichs B, Smith W, Ferre M, Terkeltaub R, Nürnberg P 2003 Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 34:379-381
38. Rutsch F, Böyer P, Nitschke Y, Ruf N, Lorenz-Depierieux B, Wit-tkampf T, Weissen-Plenz G, Fischer RJ, Mughal Z, Gregory JW, Davies JH, Loirat C, Strom TM, Schnabel D, Nürnberg P, Ter-keltaub R 2008 Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond in-fancyingeneralized arterial calcificationofinfancy. Circ Cardiovasc Genet 1:133-140
39. Terpstra L, Rauch F, Plotkin H, Travers R, Glorieux FH 2002 Bone mineralization in polyostotic fibrous dysplasia: histomorphometric analysis. J Bone Miner Res 17:1949-1953
40. Riminucci M, Collins M T, Fedarko N S, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Ge-hron Robey P 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692
41. Hoffman WH, Jueppner HW, Deyoung BR, O'dorisio M S, Given KS 2005 Elevated fibroblast growth factor-23inhypophosphatemic linear nevus sebaceous syndrome.Am JMed Genet A 134:233-236
42. Sethi SK, Hari P, Bagga A 2010 Elevated FGF-23 and parathormone in linear nevus sebaceous syndrome with resistant rickets. Pediatr Nephrol 25:1577-1578
43. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG 2009 FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 94:2332-2337
44. Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T 2009 Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 45:814-816
45. Lyles KW, Halsey DL, Friedman NE, Lobaugh B 1988 Correlations of serum concentrations of 1, 25-dihydroxyvitamin D, phosphorus, and parathyroid hormone in tumoral calcinosis. J Clin Endocrinol Metab 67:88-92
46. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T 2004 Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568
47. Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, Ze-likovic I, Raimer S, Metzker A, Richard G, Sprecher E 2004 Mutations in GALNT3, encoding a protein involved in O-linked glyco-sylation, cause familial tumoral calcinosis. Nat Genet 36:579-581
48. Frishberg Y, Ito N, Rinat C, Yamazaki Y, Feinstein S, Urakawa I, Navon-Elkan P, Becker-Cohen R, Yamashita T, Araya K, Igarashi T, Fujita T, Fukumoto S 2007 Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 22:235-242
49. Ten Hagen KG, Fritz TA, Tabak LA 2003 All in the family: the UDP-Gal N Ac:polypeptide N-acetylgalactosaminyltransferases. Glycobiology 13:1R-16R
50. Kato K, Jeanneau C, Tarp M A, Benet-PagèsA, Lorenz-Depiereux B, Bennett EP, Mandel U, Strom TM, Clausen H 2006 Polypeptide Gal N Ac-transferaseT3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 281:18370-18377
51. Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N, Yoshii N, Yamazaki Y, Yamashita T, Silver J, Igarashi T, Fujita T 2005 A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis.JClin Endocrinol Metab 90:5523-5527
52. Benet-Pagès A, Orlik P, Strom TM, Lorenz-Depiereux B 2005 An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14:385-390
53. Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT 2004 FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 89:4489-4492
54. Weber TJ, Liu S, Indridason OS, Quarles LD 2003 Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227-1234
55. Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, White KE, Econs MJ 2007 A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 117:2684-2691
56. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB 2003 Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272-2279
57. Ix JH, Shlipak MG, Wassel CL, Whooley MA 2010 Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 25:993-997
58. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M 2005 Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205-2215
59. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J 2007 The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003-4008
60. Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, Westin G, Larsson TE 2007 Fibroblast growth factor-23 regulates parathyroid hormone and 1 a-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125-131
61. Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, Tominaga Y, Otsuki N, Nibu K, Nakagawa K, Tsugawa N, Okano T, Kitazawa R, Fukagawa M, Kita T 2010 Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77:232-238
62. Jüppner H, Wolf M, Salusky IB 2010 FGF23: more than a regulator of renal phosphate handling? J Bone Miner Res 25:2091-2097
63. Wolf M 2010 Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21:1427-1435